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Female genital warts: global trends and treatments
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Department of Obstetrics and Gynecology, University of Louisville, Louisville, KY
The increasing incidence of human papillomavirus (HPV) infection and HPV-associated conditions such as genital
warts in women is a global concern. Genital warts are a clinical manifestation of HPV types 6 and 11, and are
estimated to affect 1% of sexually active adults aged between 15 and 49. HPV infection is also strongly associated
with cervical cancer,andis prevalentin as many as 99% of cases.The psychological stressof having genitalwarts is
often greater than the morbidity of the disease, and therefore successful treatment is crucial. Currenttreatments
are patient-applied and provider-administered therapies. Imiquimod 5% cream, a patient-applied therapy, is an
efficacious treatment with tolerable side-effects and a low recurrencerate, and has the potential to be an effective
strategy for the management of genital warts.
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PREVALENCE OF
HUMAN PAPILLOMAVIRUS AND
GENITAL WARTS
Human papillomavirus (HPV) infection is one of
the three most common sexually transmitted
diseases (STDs) in the United States, along with
gonorrhea and chlamydia1. It is estimated that as
many as 20–40% of sexually active women are
infected with HPV2. In the US, the estimated
number of new HPV infections each year is
5.5 million, with an estimated total prevalence of
20 million3.
Over 100different typesofHPV exist, and they
can be grouped according to their oncogenic
potential(Table1)4.HPV 6and11aretermed ‘low
risk’, as they are rarely associated with carcinomas5
and most commonly manifest as external genital
warts6. Genital warts, however, have been found
to beinducedbyother ‘high’or‘intermediate’ risk
HPVs5. Genital warts are exophytic, confluent,
cauliflower tumors and their typical morphologies
aid their diagnosis. Their most common location
in women is the vulva (Figure 1)7.
The annual incidence of genital warts has
increased steadily among women since the early
1950s,whentheestimated incidenceintheUSwas
only 13 per 100 000 for the female population8.
During the late 1970s genital wart prevalence
increased to 106 per 100 000, and at present 1% of
sexually active adults aged 15–49 are estimated to
have genital warts6. The incidence of genital warts
has also increased in Europe, with an approxi-
mately five-fold increase for females in the United
Kingdombetween1971and19949,wheretheyare
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HPV type
Oncogenic
potential
16, 18
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68
6, 11, 26, 40, 42–44, 53–55, 62, 66
High risk
Intermediate risk
Low risk
Table 1 Human papillomavirus (HPV) types and
related oncogenic risk of cervical squamous carcinoma
4now the most commonly diagnosed STD in
genitourinary medicine clinics10.
RISK FACTORS ASSOCIATED WITH
HUMAN PAPILLOMAVIRUS INFECTIONS
Two factors that clearly influence the incidence of
genital HPV infection are age and sexual behavior.
Asisthecase withothersexually transmitted infec-
tions, prevalence is reported to be highest in
sexually active young adults between 18 and 25
years of age8. Sexual behavior also has an influence
on the potential risk of being infected with HPV.
Women with five ormore partners in theprevious
5 years are over seven times more likely to have an
episodeofgenital wartsandareover 12times more
likely to have recurrent genital warts, compared
withwomenwith onesexual partnerinthistime11.
Other risk factors reported in this study were a
history of any other STDs, a history of oral herpes
or a history of allergies11. There is conflicting
evidence about whether smoking and use of oral
contraceptives are also risk factors for genital
warts11–15.
Human immunodeficiency virus (HIV) infec-
tion is an additional determining factor for infec-
tion with other STDs, including genital warts. In
one study, HIV-positive women were foundto be
over six times more likely to have genital warts,
and over three times more likely to test positive for
oncogenic HPV than HIV-negative women16.
This study reported an annual incidence rate for
genital warts in HIV-positive women of 11.4%,
compared with 1.4% in HIV-negative women16.
Furthermore, the host’s immune status is also a
factor that is important in controlling HPV infec-
tions and the development of HPV lesions such as
genital warts. This is supported by the observation
that patients who are immunosuppressed have an
increased incidence of HPV-associated lesions17.
Activation of the specific humoral and cellular
immunity pathways is reported to be important in
HPV-infected individuals for spontaneous regres-
sion of genital warts18.
HUMAN PAPILLOMAVIRUS AND
ANOGENITAL CANCER
Although genital warts are considered to be a
benign condition, an association between HPV
infection and squamous cell carcinoma (SCC) of
the anogenital tract has been identified15. Cervical
cancer is the most common type of anogenital
cancer; however, vulvar, vaginal and anal cancer
are also associated with HPV19. HPV prevalence,
in particular ‘high risk’ HPV types 16 and 18, is
greater than 99% in cervical carcinomas20. Other
HPV types that are associated with anogenital
cancer are HPV 31, 33, 35 and 45 (Table 1)21.
The increasing incidence of cervical intra-
epithelial neoplasias (CIN) in younger women22 is
of concern because of their malignant potential.
Forexample, over 30% ofCIN3 lesionsprogressto
SCC within 1–10 years22. The progression from
low-grade lesion to high-grade lesion or SCC is
also reported to occur in approximately a third
of cases22. The outcome of low-grade cervical
neoplasia is influenced by a number of factors,
including the oncogenicity of infecting HPV
type, sexual behavior, infection of the cervical
epithelium with other viral/bacterial agents, ciga-
rette smoking, oral contraceptive usage and host
immunosuppression22.
TRANSMISSION OF GENITAL WARTS
An importantissueforwomen withgenitalwartsis
theconcernabouttransmission ofHPV andgenital
warts to their sexual partners. Transmission is
believed to be predominantly through sexual
intercourse, as genital HPV is absent in the major-
ityofwomenwhohavenothadsexualintercourse.
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Figure 1 Location of genital warts in womenGenital warts in females Gall
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There have been studies, however, that have
detected HPV DNA in cervical or vulva-vaginal
samples from women who have not had sexual
intercourse8.
Transmission of HPV is enhanced when the
superficial epithelium is disrupted6, as this is where
the infectious agent resides4. The HPV life cycle
begins with infection of the basal cell layer of
the epithelium and progresses with epithelial cell
differentiation, resulting in complete virions
present in the epithelial cells in the superficial
layer4. The greatest risk of transmission is likely to
exist when genital warts are present, as they reflect
a productive HPV infection.
The risk of transmission of HPV to offspring is
also a concern. The increasing frequency of child-
hood genital warts has been proposed to be the
result of sexual abuse5. However, an association
between genital warts and cutaneous HPV 223 has
also beenreported.Theremay alsobeanon-sexual
transmission of genital warts from mothers, as well
as the possibility of transmission during passage
through the birth canal if mothers have external or
cervical genital warts5. Additional data support a
vertical (transplacental) transmission of HPV
DNA, as over50% ofchildrenbornto HPV 16- or
18-infected mothers were positive for these
HPVs24.
PSYCHOLOGICAL ASPECTS OF
GENITAL WARTS
Genital warts are not only cosmetically unaccept-
able and associated with discomfort and pain, but
theyare also associated with emotionalstress25.Itis
reported that the psychological stress of having
genital warts is often greater than the medical
effects of the disease26. Some of the psychological
outcomes of patients with genital HPV infection
are impairments to their sex life, a fear of cancer
andaworseningoftheemotionalrelationshipwith
their partner27.
In an international survey of patients’ percep-
tions about genital warts it was found that 61% of
women were ‘quite’ or ‘very’ concerned about
having genital warts25, with recurrence and trans-
mission being of the greatest concern. In total,
95% of women believed that there was a risk asso-
ciated with genital warts; the most commonly
mentionedrisks were alink tocervical cancerorto
anunspecifiedcancer.Intermsoflifestyle, approx-
imately 40% of women said that having genital
warts had changed their lifestyle. Sexual behavior
hadparticularlychanged,resultinginanincreasein
condom usage during sexual intercourse, absti-
nence from sexual intercourse, increased caution
about new partners and a decrease in the number
of sexual partners25.
TREATMENT OF GENITAL WARTS
Treatment of genital warts can be a frustrating
experience for both physician and patients28.
There are many current treatments for genital
warts; however, none are successful in all three
goals of therapy: complete eradication of warts,
maintaining clearance and eliminating the virus.
Recurrence is a substantial problem, as many
therapies do not eradicate the reservoir of HPV
DNA that is present in the tissue located adjacent
to the genital wart.
Current therapies are composed of both abla-
tive and cytodestructive modalities. Physically
ablative therapies include cryotherapy, laser
therapy, electrosurgery and surgical excision.
Manyofthephysicallyablative therapies havehigh
initial success rates; however, recurrence rates are
also high28. Cytotoxic agents that treat genital
warts destroy the affected tissue either by chemo-
destructive or antiproliferative modes of action.
Cytotoxic agents include podophyllin, podofilox
(podophyllotoxin),trichloroaceticacid(TCA)and
5-fluorouracil.
Eradication of genital warts by stimulation of
the immune system is an alternative strategy for
genital wart therapies. Interferon, an antiviral,
immunomodulatory agent is effective in treating
genital warts when administered intralesionally2,
and can be used as a treatment for recalcitrant
warts. Imiquimod is an immune response modifier
that acts to induce both humoral (innate) and
cellular immunity. The antiviral and antitumor
activity ofimiquimod isbelieved to betheresult of
the induction of cytokines such as interferon-a,
tumor necrosis factor-a and a number of specific
interleukins29. It is this stimulation of the immune
system to fight the HPV infection that is the pro-
posed mechanism for eradication of genital warts
by imiquimod.In a pivotal clinical trial, complete clearance of
lesions was observed in 72% of female patients
treated with imiquimod 5% cream, three times a
week for 16 weeks, or until warts cleared28. The
response of a genital wart in a female patient to
imiquimod treatment is shown in Figure 2. The
low recurrence rate (13%)29 in patients, an obstacle
with many of the other current therapies, is an
encouraging benefit of this treatment modality,
and may reflect the development of specific long-
term cell-mediated immunity.
Physicians have the choice between office-
based or home-based therapies. The Centers for
Disease Controland Prevention (CDC) guidelines
for the treatment of genital warts recommend that
the choice be guided by the preference of the
patient, the available resources and the experience
of the healthcare provider. It is recommended that
providers are knowledgeable about, and have
available to them, one patient-applied and one
provider-administered treatment21.
Numerous different factors can influence the
choice of treatment by the physician. Treatment
choice is based on morphology, number, distribu-
tion and the keratinization state of warts30. For
example, soft non-keratinized warts respond well
topodofiloxandTCA,whereaskeratinized lesions
are better treated with physically ablative methods
such as cryotherapy, excision or electrocautery30.
Imiquimod is suitable for both types of lesions.
The choice of treatment should be influenced
by the individual patient’s preferences and con-
venience. Patient-applied treatments may suit
patients who desire to have a less invasive form of
treatment or more control over their care. They
tend to be favored by patients owing to their con-
venience and ease of application.
Pregnancyisan importantissuein thetreatment
choice for genital warts, especially as their number
and size tend to increase during pregnancy6. It is
advocated that genital warts are removed during
pregnancy if causing complications2. Therapies
suchascryotherapy,laser therapyandTCAmaybe
used in the treatment of pregnant patients; how-
ever, the warts often spontaneously regress after
delivery5.
In addition, the cost of the treatment can influ-
ence the availability of a specific treatment choice.
In a recent US pharmacoeconomic analysis of
therapies, it was found that imiquimod is more
cost-effective thanpodofiloxas a first-line therapy,
even thoughthe average cost of treatment is lower
for podofilox. This is due to the greater sustained
clearance rate of imiquimod, compared with
podofilox31.
KNOWLEDGE AND PREVENTION OF
HUMAN PAPILLOMAVIRUS INFECTIONS
Studies of college students demonstrate a very low
knowledge and awareness of HPV infections and
genital warts1. Even though physicians provide
information about genital warts25, many patients
are still misinformed and desire additional
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Figure 2 Typical response of a genital wart in a female
patient following treatment with imiquimod 5% cream.
Photographs were taken at the beginning of treatment
(a), after 6 weeks of imiquimod treatment (b) and 4
weeks after the end of treatment (c)
a
b
cinformation. Informing adolescents and young
adults about HPV and the risks associated with
infection is an important considerationforthepre-
vention of further increases in the incidence rates
for HPV and genital warts. Aggressive health edu-
cation strategies such as classes, magazine articles
and internet information need to be employed to
remedy this situation.
There is no simple method of preventing infec-
tion with HPV other than abstinence from sexual
intercourse,anapproachthathasbeenshowntobe
relatively ineffective. HPV can be present in cells
throughoutthe genital tract1, and is transmitted by
skin-to-skincontact.Barrier methodsofbirthcon-
trol, which do reduce transmission, do not elimi-
nate the possibility of infection1. A recent survey
reported that approximately one-third of women
attempt to prevent transmission of their genital
warts by condom usage25. However, there is a risk
of transmission from lesions that are not shielded
by a condom25. It is still unknown at which stage
patients with genital warts are infectious, and
whether the elimination of the wart itself influ-
ences infectivity2.
Prevention ofcervical cancerrelies primarily on
thedetection ofintraepithelial disease throughPap
smear screening1, as opposed to the prevention of
initial infection with HPV. Theprospectof testing
for HPV DNA in conjunction with Pap smears is
currently under consideration32.
CONCLUSIONS
The increasing incidence of HPV infection and
genital warts highlights the need for an effective
strategy in the management of this disease. Even
though many different treatment modalities exist,
none of these have actually been proven to ‘cure’
the disease. New therapies such as imiquimod are
improving therapeutic outcomes, but increasing
public knowledge about prevention and trans-
mission ofHPVand genitalwartsisfundamentalin
the fight against these conditions.
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